American Clean Resources Stock (OTC: ACRG)

American Clean Resources (OTC:ACRG) Stock, Quote.Headers.trade-ideas

American Clean Resources Group Inc is an exploration stage company that plans to be a custom processing and permitted toll milling service provider for minerals in the gold, silver, and platinum metal groups. The company seeks to provide toll milling and refining services by building a facility on its Tonopah property which includes an analytical lab, pyrometallurgical, and hydrometallurgical recovery plant.

Image generated with Free AI Art Generator // Image license: CC0

Cannabis

News

Penny Stocks

Markets

ACRDF

ACRG

ACRHF

GNLN

Hey there, cannabis enthusiasts! Get ready for an exciting weekly roundup of the hottest cannabis product releases, brought to you by Benzinga.

New Cannabis Products For Your Vacation: THC Lemonades, Mini Pre-Rolls, Laser Bongs, Concentrate Vapes And More!

Image by Luke Stackpoole On Unsplash

Government

Regulations

Politics

Retail Sales

General

New York&#39;s Office of Cannabis Management (OCM) has unveiled an innovative plan to introduce cannabis farmers&#39; markets this summer as a way of tackling the supply chain challenges caused by limited retail outlets across the state. 

New York Introduces Cannabis Farmers&#39; Markets To Address Supply Chain Glut And Lack Of Retail Shops

AMERICAN CLEAN RESOURCES by American Clean Resources Group Inc.

American Clean Resources Group Inc

ACREAGE HOLDINGS FX SUB VOT CL E ORD

ACREAGE HOLD FLOAT SUB VOT CL D ORD

<ul>
<li>Sonim&#39;s XP400 and XP100 Set to Disrupt the Rugged Professional Segment with Unmatched Quality with Competitive Pricing; Available&nbsp;Q4&nbsp;2024</li>
</ul>

SONM

Reported Saturday, Sonim Technologies Launches Rugged Phones XP400 And XP100 For EMEA At IFA Berlin

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled lower on Friday, with the S&amp;P 500 logging its worst week since March 2023. Megacap tech stocks moved lower with investors dumping risk assets. Shares of Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) dipped 3.7%, while Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) shares tumbled 4.1% during the session. Shares of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dipped 4.1% on Friday.
On the economic data front, the U.S. economy added 142,000 jobs in August versus a revised 89,000 gain in July, but down from market estimates of 160,000. The unemployment rate fell to 4.2% in August from 4.3% in the previous month. Average hourly earnings for all employees rose by 0.4% to $35.21 in August compared to a 0.2% gain in July.
Most sectors on the S&amp;P 500 closed on a negative note, with communication services, information technology and consumer discretionary stocks recording the biggest losses on Friday. However, real estate stocks bucked the overall market trend, closing the session slightly higher.
The Dow Jones closed lower by around 410 points to 40,345.41 on Friday. The S&amp;P 500 fell 1.73% to 5,408.42, while the Nasdaq Composite dipped 2.55% to 16,690.83 during Friday's session.
Investors are awaiting earnings results from Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), Mission Produce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) and Matrix Service Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 39.3, the index moved to the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 47.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40748893/over-40m-bet-on-pbf-energy-check-out-these-4-stocks-executives-are-buying">Over $40M Bet On PBF Energy? Check Out These 4 Stocks Executives Are Buying</a></li>
</ul>

Equities

AMZN

GOOG

GOOGL

MTRX

NVDA

ORCL

S&P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear & Greed Index Moves To 'Fear' Zone

<ul>
<li>Objective response rate of&nbsp;54.8%&nbsp;seen with Daiichi Sankyo and Merck&#39;s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients</li>
<li>12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study</li>
</ul>

DSNKY

Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to report quarterly earnings at $1.32 per share on revenue of $13.23 billion after the closing bell. Oracle shares fell 0.2% to $141.49 in after-hours trading.</li>
<li>BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) shares surged in after-hours trading on Friday after BlackSky Geospatial Solutions was named in a NASA Commercial SmallSat Services Award. BlackSky Technology shares climbed 13.8% to $0.8840 in the after-hours trading session.</li>
<li>Analysts are expecting Mission Produce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) to post quarterly earnings at 3 cents per share on revenue of $230.95 million. The company will release earnings after the markets close. Mission Produce shares fell 1.1% to $10.61 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Hyzon Motors Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) announced a 1-for-50 reverse stock split, effective Sept. 11, 2024. Hyzon shares fell 15.5% to $0.0549 in the after-hours trading session.</li>
<li>Analysts expect Matrix Service Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>) to report a quarterly loss at 21 cents per share on revenue of $202.81 million after the closing bell. Matrix Service shares fell 0.5% to close at $9.37 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40748893/over-40m-bet-on-pbf-energy-check-out-these-4-stocks-executives-are-buying">Over $40M Bet On PBF Energy? Check Out These 4 Stocks Executives Are Buying</a></li>
</ul>

Earnings

Pre-Market Outlook

Trading Ideas

BlackSky Technology Inc. Class A Common Stock

BKSY

HYZN

Oracle, Mission Produce And 3 Stocks To Watch Heading Into Monday

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk on Sunday <a href="https://www.benzinga.com/news/24/09/40764724/elon-musks-xai-eyes-share-of-future-tesla-revenue-in-potential-deal">denied reports</a> of his artificial intelligence startup xAI discussing a deal with his EV company for a share of its revenue in return for providing the carmaker access to the AI startup&#8217;s technology and resources. 
What Happened: &#8220;Tesla has learned a lot from discussions with engineers at xAI that have helped accelerate achieving unsupervised FSD, but there is no need to license anything from xAI,&#8221; Musk wrote on X.
xAI&#8217;s artificial intelligence models are &#8220;gigantic&#8221; and couldn&#8217;t possibly run on the Tesla&#8217;s in-vehicle inference computer, the CEO added. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Haven't read the article, but the above is not accurate. Tesla has learned a lot from discussions with engineers at xAI that have helped accelerate achieving unsupervised FSD, but there is no need to license anything from xAI. The xAI models are gigantic, containing, in…
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1832618127189774374?ref_src=twsrc%5Etfw">September 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The Wall Street Journal reported on Saturday that xAI&nbsp;is discussing a potential deal with Tesla. The deal would involve Tesla licensing <a href="https://www.benzinga.com/general/social-media/24/09/40760039/elon-musk-less-influential-to-artificial-intelligence-than-scarlett-johansson-time-magazine-">AI models from xAI </a>for its Full Self-Driving (FSD) driver assistance software, the report said, citing people familiar with the matter.
WSJ reported that the proposed deal would entail Tesla sharing a portion of its revenue with xAI. xAI would also contribute to the development of additional features for Tesla, such as a voice assistant similar to Siri and software for Tesla's humanoid robot, Optimus, the report said. 
The specifics of the revenue-sharing agreement would be contingent on the extent to which Tesla utilizes xAI's technology in comparison to its own, WSJ added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40766744/elon-musk-says-tesla-will-open-a-lot-more-superchargers-asks-ev-enthusiasts-for-input-on-where-to-in">Elon Musk Says Tesla Will Open &#8216;A Lot More Superchargers,&#8217; Asks EV Enthusiasts For Input On Where To Install Them Next</a></li>
</ul>
Image made via photos on Shutterstock

Tech

TSLA

Elon Musk Refutes Reports Of xAI Negotiating Revenue Share Deal With Tesla: 'There Is No Need To License Anything'

Biotech

Large Cap

Health Care

AstraZeneca And Daiichi Sankyo's Datopotamab Deruxtecan Demonstrated Meaningfully Greater Magnitude Of Progression-free Survival Benefit In Non-Small Cell Lung Cancer Patients With TROP2 Biomarker In TROPION-Lung01 Phase 3 Trial

EMCG

Reported Sunday, Embrace Change Receives Nasdaq Warning For Delayed Quarterly Report, Plans To File By End Of September

Immunovant, Inc. (Nasdaq: IMVT), a&nbsp;clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food &amp; Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.

IMVT

Immunovant Reports Phase 2a Results for Graves' Disease Drug, FDA Clears Pivotal Trial

As Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) prepares to unveil its highly anticipated iPhone 16 lineup tomorrow, prominent Wall Street analyst Dan Ives of Wedbush Securities is forecasting a potential watershed moment for the tech giant. 
What Happened: In a research note released on Sunday, Wedbush claims that the iPhone 16 launch could kick off &#8220;Cupertino&#8217;s biggest upgrade cycle in its history.&#8221;
Ives, known for his bullish stance on Apple, cites the integration of artificial intelligence as a key driver for this predicted supercycle. 
&#8220;This iPhone 16 release is all about Apple Intelligence and the unleashing of the consumer AI Revolution through Cupertino,&#8221; Ives writes. He estimates that approximately 20% of consumers worldwide will ultimately access and interact with generative AI apps through the Apple ecosystem in the coming years.
The Wedbush analyst&#8217;s optimism is further bolstered by his supply chain checks, which indicate stronger-than-expected initial shipments for the iPhone 16. Ives projects shipments closer to 90 million units, surpassing earlier Street expectations of 80 to 84 million. This represents a double-digit year-over-year increase.
Looking ahead, Ives believes Apple could sell north of 240 million iPhone units in fiscal year 2025 as the AI-driven upgrade cycle takes hold. He maintains an outperform rating on Apple stock with a price target of $285.
Ives also highlights the strategic importance of Apple&#8217;s AI push, suggesting that the company will become &#8220;the gatekeeper of the consumer AI Revolution.&#8221; He expects developers to create hundreds of generative AI-driven apps for the Apple ecosystem within the next 6 to 12 months.
As for the iPhone 16 itself, Ives anticipates larger displays for the Pro models, the introduction of the A18 chip (with an A18 Pro variant for higher-end models), enhanced battery life, and improved camera technology. He expects Apple to maintain similar price points to the iPhone 15 to encourage widespread adoption of AI-enhanced devices.
With the launch event set for tomorrow at Apple Park, all eyes will be on CEO Tim Cook and his team to see if they can deliver on the lofty expectations set by analysts like Ives. If his predictions hold true, we may indeed be witnessing the dawn of what Ives calls &#8220;the next leg of the Apple growth story.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/09/40764465/dont-believe-the-hype-about-an-iphone-16-super-cycle-gurman-says-consumers-will-have-to-wait-for-the">&#8216;Don&#8217;t Believe The Hype About An iPhone 16 Super Cycle,&#8217; Gurman Says: &#8216;Consumers Will Have To Wait For The Best AI Features&#8217;</a>

Why It Matters: The iPhone 16 launch, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40713896/apples-glowtime-event-will-the-iphone-16-shine-or-fizzle">dubbed the &#8220;Glowtime&#8221; event</a>, has been a focal point for tech enthusiasts. The event, is expected to unveil the iPhone 16 series alongside potential updates to Apple Watches and AirPods.


Moreover, the new iPhone <a href="https://www.benzinga.com/news/24/09/40766753/iphone-16-to-feature-arms-next-gen-ai-chip-technology-what-you-should-know-about-apples-move">series will be powered</a> by ARM Holdings&#8216; next-gen AI chip technology, enhancing its AI capabilities. 


In addition, Apple may discontinue all three models of EarPods, including USB-C, as hinted by a <a href="https://www.benzinga.com/news/24/09/40766000/apple-may-discontinue-all-three-earpods-models-including-usb-c-researcher-hints-at-target-listing-cl">researcher</a> on Sunday. This move could further streamline Apple&#8217;s product lineup, focusing consumer attention on the new iPhone 16 and <a href="https://www.benzinga.com/news/24/09/40766000/apple-may-discontinue-all-three-earpods-models-including-usb-c-researcher-hints-at-target-listing-cl">its advanced features</a>.

Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40758803/did-a-potential-stock-sale-by-elon-musk-lead-to-fall-in-tesla-shares-top-analyst-sa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Did A Potential Stock Sale By Elon Musk Lead To Fall In Tesla Shares? Top Analyst Says It Could Instead Be Because Of Broader Selloff In AI Stocks</a></li>
</ul>
Apple Glowtime logo courtesy of Apple.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Global

AAPL

iPhone 16 Could Kick Off 'Biggest Upgrade Cycle' In Apple's History, Says Dan Ives: Wedbush Analyst Predicts 'AI Revolution' Through Cupertino

<ul>
<li>Bexicaserin achieved an overall median seizure reduction of&nbsp;57.7%&nbsp;in countable motor seizures over an approximate 9-month treatment period</li>
<li>Favorable safety and tolerability results continue to be observed</li>
<li>Data to be presented at the 15th&nbsp;European Epilepsy Congress in Rome, Italy</li>
<li>Full 12-month OLE dataset expected early next year</li>
</ul>

LBPH

Reported Sunday, Longboard Pharmaceuticals Reports Interim Results From Phase 1b/2a PACIFIC Study, Showing 57.7% Seizure Reduction In DEE Patients

<ul>
<li>Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Weeks 24 and 48</li>
<li>Responder Analysis Results for Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO%) Showed Significantly Higher Proportions of Molgramostim Responders Compared with Placebo at Weeks 24 and 48</li>
<li>Responder Analysis Results for St. George&#39;s Respiratory Questionnaire (SGRQ) Total Score Supported Numeric and Significant Improvements with Molgramostim Compared with Placebo at Weeks 24 and 48, Respectively</li>
<li>Ground Glass Opacification (GGO) Score, a Measure of Surfactant Burden, Significantly Improved with Molgramostim Compared with Placebo at Week 24</li>
</ul>

SVRA

Reported Sunday, Savara Unveils Phase 3 IMPALA-2 Trial Data On Molgramostim For Autoimmune Pulmonary Alveolar Proteinosis At ERS Congress 2024

Academy Sports and Outdoors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NYSE">ASO</a>) will release earnings results for its second quarter, before the <a href="https://www.benzinga.com/quote/ASO/earnings">opening bell on Tuesday, Sept. 10.</a>
Analysts expect the Katy, Texas-based company to report quarterly earnings at $2.03 per share, down from $2.09 per share in the year-ago period. Academy Sports and Outdoors is projected to post revenue of $1.57 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 5, Academy Sports and Outdoors' board approved the declaration of a quarterly cash dividend of 11 cents per share.
Academy Sports and Outdoors shares fell 0.4% to close at $53.58 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e301e08430dee0001c88c8d/joseph-feldman">Telsey Advisory Group analyst Joseph Feldman </a>maintained an Outperform rating with a price target of $65 on Sept. 5. This analyst has an accuracy rate of 70%.</li>
<li>Wedush analyst Seth Basham reiterated an Outperform rating with a price target of $65 on Sept. 5. This analyst has an accuracy rate of 70%.</li>
<li>TD Cowen analyst John Kernan downgraded the stock from Buy to Hold and cut the price target from $58 to $54 on Aug. 13. This analyst has an accuracy rate of 71%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d9ee7bf6000154d225/christopher-horvers">JP Morgan analyst Christopher Horvers </a>downgraded the stock from Overweight to Neutral and slashed the price target from $76 to $53 on Aug. 5. This analyst has an accuracy rate of 73%.</li>
<li>Evercore ISI Group analyst Greg Melich maintained an Outperform rating and raised the price target from $60 to $70 on June 20. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying ASO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="516" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09025120/image-59-1024x516.png" alt="" class="wp-image-536520" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09025120/image-59-1024x516.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09025120/image-59-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09025120/image-59-768x387.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09025120/image-59.png 1335w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40748893/over-40m-bet-on-pbf-energy-check-out-these-4-stocks-executives-are-buying">Over $40M Bet On PBF Energy? Check Out These 4 Stocks Executives Are Buying</a>

Price Target

Analyst Ratings

Top Wall Street Forecasters Revamp Academy Sports and Outdoors Price Expectations Ahead Of Q2 Earnings

Elon Musk‘s spacecraft manufacturing company&nbsp;SpaceX&nbsp;said on Sunday that it is now looking to launch its all-civilian <a href="https://www.benzinga.com/news/24/08/40644887/polaris-dawns-all-civilian-crew-continues-in-quarantine-as-spacex-delays-launch-space-exploration-de">Polaris Dawn mission</a> after multiple delays on Sept. 10. 
What Happened: SpaceX is now planning to launch the mission to space from Florida on Tuesday at 3:38 a.m. ET. There are two additional launch opportunities at 5:23 a.m. ET and 7:09 a.m. on the same day, the company said.
&#8220;Weather is currently 40% favorable for liftoff, and conditions at the possible splashdown sites for Dragon's return to Earth remain a watch item,&#8221; SpaceX said on Sunday, hinting that the mission might be delayed yet again if the weather conditions are deemed not favorable. 
The Polaris Dawn mission was initially&nbsp;<a href="https://www.benzinga.com/news/24/08/40501311/spacex-delays-launch-of-private-human-spaceflight-mission-polaris-dawn-program-founder-jared-isaacma" target="_blank" rel="noreferrer noopener">slated to launch in late August</a>&nbsp;but has been postponed multiple times since owing to a<a href="https://www.benzinga.com/news/24/08/40569255/spacex-postpones-landmark-polaris-dawn-mission-launch-to-wednesday-after-identifying-helium-leak-elo" target="_blank" rel="noreferrer noopener">&nbsp;helium leak</a>&nbsp;and&nbsp;<a href="https://www.benzinga.com/news/24/08/40592730/spacexs-first-commercial-spacewalk-delayed-by-unfavorable-weather-elon-musk-led-company-has-no-new-d" target="_blank" rel="noreferrer noopener">unfavorable weather forecast.</a>&nbsp;SpaceX is prioritizing crew safety given the increased risk associated with the mission, Musk previously explained.
Why It Matters:&nbsp;Polaris Dawn is the first of up to three human spaceflight missions planned under the Polaris program founded by Shift4 Payments&nbsp;CEO&nbsp;Jared Isaacman.
SpaceX's Dragon spacecraft and the all-civilian Polaris Crew composed of four including its mission commander&nbsp;<a href="https://www.benzinga.com/sec/insider-trades/0001805608/jared-isaacman" target="_blank" rel="noreferrer noopener">Isaacman</a>, Kidd Poteet, Sarah Gillis, and Anna Menon will spend up to five days in orbit. While Isaacman and Poteet work together at Shift4, Gillis and Menon are SpaceX engineers.
The key objective of the mission is to&nbsp;<a href="https://www.benzinga.com/news/24/08/40437487/elon-musk-says-polaris-dawn-mission-will-be-epic-as-spacex-gears-up-for-its-first-spacewalk" target="_blank" rel="noreferrer noopener">conduct a spacewalk</a>&nbsp;nearly 435 miles above the Earth — marking the first-ever spacewalk by a commercial company. While space agency NASA routinely conducts extravehicular activities, no private player has attempted it before, making this a landmark mission for SpaceX and commercial spaceflight companies.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40744852/elon-musks-spacex-rockets-past-new-milestone-launches-7-000th-starlink-satellite" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s SpaceX Rockets Past New Milestone, Launches 7,000th Starlink Satellite</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

SpaceX Set To Launch All-Civilian Polaris Dawn Mission On September 10 After Multiple Delays

Top analyst Ming-Chi Kuo has <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40645921/apple-intelligence-will-play-starring-role-in-iphone-16-launch-says-analyst-no-pric">shared production data</a>&nbsp;for Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iPhone 16 series, providing details on shipment plans for the third and fourth quarters of 2024 and the first quarter of 2025.
What Happened: In a blog post shared on Monday, Kuo revealed that the&nbsp;2024 shipment forecast for the&nbsp;iPhone 16 series has been slightly raised&nbsp;from 87–88 million units to&nbsp;88–89 million units, primarily due to increased demand for the standard iPhone 16.
The iPhone 16 series, comprising the&nbsp;standard version, iPhone 16 Plus,&nbsp;iPhone 16 Pro, and iPhone&nbsp;16 Pro Max, is projected to&nbsp;account for approximately 26%, 6%,&nbsp;30%, and 38% of iPhone&nbsp;16 series shipments in 2024,&nbsp;respectively.
Shipments&nbsp;for August and September are&nbsp;expected to be&nbsp;around 9 million and 16&nbsp;million units, respectively. Kuo estimates that&nbsp;Apple is preparing&nbsp;15–17 million units for iPhone&nbsp;16 pre-orders.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/40679223/mark-cuban-explains-why-despite-getting-a-lot-of-flak-from-elon-musk-and-others-he-continues-to-post?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Explains Why, Despite Getting A Lot Of Flak From Elon Musk And Others, He Continues To Post On X: ‘Don't Want to Be Where Everyone Agrees with Me'</a>
Meanwhile, in the third quarter of 2024 iPhone 16 series shipments&nbsp;are expected to grow about&nbsp;10% YoY compared to the same period last year with&nbsp;iPhone 15 series. 
However, for the fourth-quarter 2024&nbsp;iPhone 16 series shipments are&nbsp;projected to decline by 5–7% YoY&nbsp;compared to the same time last year iPhone 15&nbsp;series.
In the first quarter of 2025,&nbsp;iPhone 16 series shipments are&nbsp;expected to decline significantly by&nbsp;53–55% QoQ, primarily due to&nbsp;seasonality and the potential cannibalization&nbsp;impact of the new iPhone&nbsp;SE4.
Kuo also revealed that&nbsp;the only iPhone EMS providers&nbsp;are now Foxconn and Luxshare&nbsp;ICT,&nbsp;responsible for 55–60% and 40–45%&nbsp;of iPhone 16 series shipments, respectively.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">iPhone 16系列生產資料更新： 3Q24、4Q24與1Q25的出貨計畫、 EMS的訂單比重等 / iPhone 16 series production data update: shipment plans for 3Q24, 4Q24 and 1Q25, EMS order allocations, etc<a href="https://t.co/quv9HKsWLf">https://t.co/quv9HKsWLf</a>
&mdash; 郭明錤 (Ming-Chi Kuo) (@mingchikuo) <a href="https://twitter.com/mingchikuo/status/1833017269196296266?ref_src=twsrc%5Etfw">September 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Before the iPhone 16 launch, experts had mixed views. Gene Munster, a tech expert, suggested that the iPhone 16 launch could be a&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40696588/exclusive-apples-iphone-16-launch-will-be-disappointment-before-the-excitement-gene">&#8220;disappointment before the excitement,&#8221;</a> as much of the anticipation was already factored into the stock.
However, he believed the new phone would boost the stock over the next year. &#8220;I think it's conservative to say 10% because there's a group that's just going upgrade this year because it's time. Their phone is five years old they're just gonna get a new phone.&#8221;
On the other hand, Bloomberg columnist Mark Gurman cautioned consumers not to believe the hype about an iPhone 16 super cycle, stating that the&nbsp;<a href="https://www.benzinga.com/news/24/09/40764465/dont-believe-the-hype-about-an-iphone-16-super-cycle-gurman-says-consumers-will-have-to-wait-for-the">&#8220;best AI features&#8221;</a>&nbsp;would require a wait.
Meanwhile, just days before the iPhone 16 launch, Huawei&#8217;s new tri-fold smartphone, the Mate XT, received <a href="https://www.benzinga.com/news/24/09/40765746/apples-iphone-16-launch-parade-on-monday-gets-rained-on-by-huawei-chinese-companys-tri-fold-phone-ge">over a million orders in just seven hours</a>, potentially raining on Apple&#8217;s parade.
Image via Shutterstock
Check out more of&nbsp;Benzinga's&nbsp;Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40737548/apple-iphone-16-event-not-sell-the-news-analyst-says-shares-could-move-higher?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple iPhone 16 Event Not ‘Sell The News,' Analyst Says: ‘Shares Could Move Higher'</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

iPhone 16 Series Production Data Unveiled By Top Apple Analyst: 9M To 16M Units Shipments For August And September Expected

CNBC&#8217;s &#8220;Mad Money&#8221; host Jim Cramer called Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) the &#8220;most vulnerable&#8221; among the Magnificent 7 stocks.
What Happened: Cramer has identified Apple as the most susceptible stock among the &#8220;Magnificent 7&#8221; ahead of the iPhone 16 launch, CNBC <a href="https://www.cnbc.com/2024/09/08/jim-cramer-says-apple-aapl-is-vulnerable-ahead-of-iphone-16-launch.html">reported</a> on Monday.
In a note on Sunday, Cramer expressed concerns about the valuation of the top seven tech companies, including Apple, which he believes has become overvalued despite recent sell-offs.
Cramer emphasized that investors have stopped considering the price at which they buy these stocks, leading to inflated valuations. He noted that Apple&#8217;s upcoming iPhone 16 launch could be a critical event for the company&#8217;s stock performance.
He also pointed out that Apple&#8217;s partnership with OpenAI to integrate ChatGPT into its devices, announced in June, has created high expectations. However, Cramer remains cautious about the stock&#8217;s future amid these developments.
See Also: <a href="https://www.benzinga.com/news/24/09/40743718/mark-cuban-says-kamala-harris-is-simply-doing-what-trump-did-in-2016-its-her-party-she-gets-to-set-t?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says Kamala Harris Is Simply Doing What Trump Did In 2016: &#8216;It&#8217;s Her Party. She Gets To Set The Rules&#8217;</a>
Why It Matters: The upcoming iPhone 16 launch, dubbed the &#8220;Glowtime&#8221; event, is highly anticipated. Apple has been at the center of tech news, with the event expected to <a href="https://www.benzinga.com/24/09/40763490/apples-glowtime-iphone-16-launch-oled-display-upgrades-and-huaweis-countermove-this-week-in-applever">showcase significant upgrades</a>, including OLED displays. However, competition is heating up, with<a href="https://www.benzinga.com/24/09/40763490/apples-glowtime-iphone-16-launch-oled-display-upgrades-and-huaweis-countermove-this-week-in-applever"> Huawei making unexpected moves</a> that could impact Apple&#8217;s market share.
Analysts have mixed opinions on Apple&#8217;s stock performance post-event. While some believe the iPhone 16 launch could drive the stock higher, others, like Cramer, are cautious. An analyst recently noted that the iPhone 16 event might not be a &#8220;sell the news&#8221; moment, suggesting that Apple&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40737548/apple-iphone-16-event-not-sell-the-news-analyst-says-shares-could-move-higher">shares could move higher</a>.
Additionally, a recent poll revealed that investors are considering other options within the &#8220;Magnificent 7&#8221; for retirement investments, with Amazon.com emerging as a <a href="https://www.benzinga.com/top-stories/24/08/40602271/ready-to-retire-on-a-single-magnificent-7-stock-poll-reveals-top-pick-and-its-not-apple">top pick over Apple</a>. This indicates a shift in investor sentiment, potentially impacting Apple&#8217;s stock performance.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40758803/did-a-potential-stock-sale-by-elon-musk-lead-to-fall-in-tesla-shares-top-analyst-sa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Did A Potential Stock Sale By Elon Musk Lead To Fall In Tesla Shares? Top Analyst Says It Could Instead Because Of Broader Selloff In AI Stocks</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Analyst Color

Jim Cramer Warns Apple Is 'Most Vulnerable' Among Magnificent 7 Stocks Ahead Of iPhone 16 Launch

<ul>
<li>New longer-term data from the&nbsp;MARIPOSA&nbsp;study confirm superior outcomes of chemotherapy-free RYBREVANT&reg;&nbsp;plus LAZCLUZE&trade; regimen compared to osimertinib monotherapy as first-line therapy</li>
<li>Results from an interim analysis featured in late-breaker oral presentation at WCLC</li>
<li>At three years (a median follow-up of 31.1 months),&nbsp;61 percent&nbsp;of patients receiving RYBREVANT&reg;&nbsp;plus LACLUZE&trade; were alive compared to&nbsp;53 percent&nbsp;of those treated with osimertinib based on an analysis performed at the request of a health authority (Median OS not estimable vs 37.3 months; hazard ratio [HR], 0.77; [95 percent&nbsp;confidence interval [CI], 0.61-0.96]; nominal&nbsp;P=0.019). Overall survival will continue to be assessed with longer term follow-up as a key secondary endpoint. The primary efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR).1</li>
</ul>

Reported Sunday, Johnson & Johnson Unveils Long-Term Data From MARIPOSA Study Showing RYBREVANT Plus LAZCLUZE Outperforming Osimertinib In Lung Cancer Treatment

CCCC

Reported Sunday, C4 Therapeutics To Reveal Preliminary CFT1946 Monotherapy Phase 1 Clinical Data At ESMO Congress 2024

MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024.
&nbsp;

MGNX

Reported Sunday, MacroGenics To Present Phase 2 Results From TAMARACK Trial On Innovative Cancer Treatment At ESMO 2024

Presentations include abstracts from the GALAXY arm of the CIRCULATE-Japan trial, along with new data in Breast Cancer and Squamous Cell Carcinoma of the Head and Neck
Natera, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain.
Natera and its collaborators will present a total of nine abstracts, including five poster presentations from the GALAXY observational arm of the CIRCULATE-Japan trial, one of the largest and most comprehensive prospective studies of MRD testing in resectable colorectal cancer (CRC).

NTRA

Reported Sunday, Natera To Present Key Findings From CIRCULATE-Japan Trial At ESMO 2024, Showcasing 10X Survival Advantage With Signatera

Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora Pharmaceuticals Ophthalmic (hereinafter referred to as "Bora," 6472.TW). Formosa Pharma's U.S. partner, Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>), has initiated the pre-launch activities for APP13007 and is expected to begin commercialization in late September.
&nbsp;
APP13007, developed through Formosa Pharma's proprietary APNT&#xAE; nanotechnology platform, is the first drug approved by the U.S. FDA for ophthalmic use utilizing the super-potent corticosteroid, clobetasol propionate. Almost 7 million ophthalmic surgeries are performed annually in the U.S., and the ophthalmic steroid and steroid-combination drug market is valued at USD $1.3 billion. According to a recent survey conducted by Eyenovia of 100 U.S. ophthalmic surgeons, efficacy and cost were identified as the most important factors when choosing a treatment for postoperative inflammation and pain. APP13007 offers a more convenient dosing regimen with its proven efficacy, requiring only twice-daily administration compared to other treatments that require up to four doses per day.

EYEN

Formosa Pharma and Eyenovia Set to Launch New FDA-Approved Ophthalmic Drug in US

American Clean Resources signs a Well Water Purchase Agreement

American Clean Resources Group (ACRG) has shared an update. American Clean Resources Group, Inc. has expanded its Board of Directors and has welcom...

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Comments

American Clean Resources

American Clean Resources (ACRG) Forecast

American Clean Resources (OTC:ACRG) Stock, Quote.Headers.trade-ideas